| Year |
Citation |
Score |
| 2018 |
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, et al. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. Oncotarget. 9: 33995-34008. PMID 30338041 DOI: 10.18632/oncotarget.26129 |
0.332 |
|
| 2016 |
Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences. 8: 99-128. PMID 27617040 DOI: 10.1007/s12561-014-9124-2 |
0.527 |
|
| 2016 |
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, et al. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27480147 DOI: 10.1200/Jco.2015.66.0084 |
0.321 |
|
| 2015 |
Liu S, Lee JJ. An overview of the design and conduct of the BATTLE trials. Chinese Clinical Oncology. 4: 33. PMID 26408300 DOI: 10.3978/j.issn.2304-3865.2015.06.07 |
0.307 |
|
| 2013 |
Gu X, Yin G, Lee JJ. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemporary Clinical Trials. 36: 642-50. PMID 24075829 DOI: 10.1016/J.Cct.2013.09.009 |
0.513 |
|
| 2013 |
Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 436-42. PMID 23442309 DOI: 10.1097/JTO.0b013e318287c91e |
0.319 |
|
| 2012 |
Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1645-52. PMID 23059780 DOI: 10.1097/JTO.0b013e31826910ff |
0.341 |
|
| 2011 |
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery. 1: 44-53. PMID 22586319 DOI: 10.1158/2159-8274.CD-10-0010 |
0.35 |
|
| 2011 |
Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1490-501. PMID 21163870 DOI: 10.1158/1078-0432.Ccr-10-2703 |
0.524 |
|
| 2010 |
Gu X, Lee JJ. A simulation study for comparing testing statistics in response-adaptive randomization. Bmc Medical Research Methodology. 10: 48. PMID 20525382 DOI: 10.1186/1471-2288-10-48 |
0.473 |
|
| 2010 |
William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 116: 2401-8. PMID 20225327 DOI: 10.1002/cncr.24996 |
0.303 |
|
| 2009 |
Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prevention Research (Philadelphia, Pa.). 2: 702-11. PMID 19638491 DOI: 10.1158/1940-6207.Capr-09-0084 |
0.536 |
|
| Show low-probability matches. |